Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27621962
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Int+J+MCH+AIDS
2012 ; 1
(1
): 92-101
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Biochemical Manifestation of HIV Lipodystrophy Syndrome
#MMPMID27621962
Ihenetu K
; Mason D
Int J MCH AIDS
2012[]; 1
(1
): 92-101
PMID27621962
show ga
OBJECTIVES: Highly active anti-retroviral therapy (HAART), including protease
inhibitors (PI) have led to dramatic improvements in the quality and quantity of
life in patients with acquired immunodeficiency syndrome (AIDS). However, a
significant number of AIDS patients on HAART develop characteristic changes in
body fat redistribution referred to as lipodystrophy syndrome (LDS). Features of
LDS include hypertrophy in the neck fat pad (buffalo hump), increased fat in the
abdominal region (protease paunch), gynecomastia and loss of fat in the mid-face
and extremities. METHODS: The aim of this paper is to review the current
knowledge regarding this syndrome. This article reviews the published
investigations on biochemical manifestation of HIV lipodystrophy syndrome.
RESULTS: It is estimated that approximately 64% of patients treated with PI will
experience this syndrome. Biochemically, these patients have increased
triglycerides (Trig), total cholesterol (TC), low-density lipoprotein-cholesterol
(LDL-C) and extremely low high-density lipoprotein-cholesterol (HDL-C).
CONCLUSIONS AND PUBLIC HEALTH IMPLICATIONS: It is hoped that awareness of this
syndrome would aid in early diagnosis and better patient management, possibly
leading to a lower incidence of cardiovascular complications among these
patients.